More MS news articles for Feb 2002

International consensus statement on the use of disease-modifying agents in multiple sclerosis

http://www.ingenta.com/isis/searching/ExpandTOC/ingenta?issue=infobike://arn/ms/2002/00000008/00000001&index=5

Multiple Sclerosis,
1 February 2002, vol. 8, no. 1,   pp. 19-23(5)
Freedman M S[1]; Blumhardt L D[2]; Brochet B[3]; Comi G[4]; Noseworthy J H[5]; Sandberg-Wollheim M[6]; Soelberg Sørensen P[7]
[1] Sclerosis Research Clinic, The Ottawa Hospital - General Campus, 501 Smyth Road, Ottawa, Ontario, Canada K1H 8L6
[2] Division of Clinical Neurology, University Hospital, Queen's Medical Centre, Nottingham NG7 2UH, UK
[3] Service de Neurologie, Hôpital Pellegrin, Fédéeration des Neurosciences Cliniques du CHU de Bordeaux, Bordeaux Cedex 33076, France
[4] Department of Neurophysiology, University of Milan, IRCCS Ospedale San Raffaele, via Olgettina 60, Milan 20132, Italy
[5] Department of Neurology, Mayo Clinic, Rochester, Minnesota 55095, USA
[6] Department of Neurology, Lund Hospital, Lund S-22185, Sweden
[7] Neuroscience Centre, Copenhagen University Hospital, Copenhage D-2100, Denmark
 
Abstract:

Objective:

To provide recommendations on the use of disease-modifying agents in the management of multiple sclerosis (MS) and to ensure that treatment will be available to those patients who may benefit.

Methods:

An initial draft of the consensus statement was prepared by the Steering Committee and amended in the light of written comments from a group of MS specialists. At a subsequent workshop, the wording of the consensus statement was discussed, modified if necessary, and the participants indicated their level of support using an electronic voting system. A new draft of the statement was then sent to a much larger group of international opinion leaders in MS for further comment.

Results:

A number of statements were agreed, which outline the criteria for consideration of disease-modifying therapy for MS and recommendations for treatment. Each statement was accepted completely, or with only minor reservations by 95% or more of those present at the workshop.

Conclusions:

Periodic reviews and modifications to the statement will be required, as new approaches to the treatment of MS and other therapeutic agents become available.
 

© 2002 ingenta